Gilead Sciences is opening up its checkbook yet again to add another cancer therapy to its pipeline, this time committing $120 million to Jounce Therapeutics for rights to an antibody drug approaching clinical testing.
The Jounce (NASDAQ: JNCE) drug, JTX-1811, is intended to selectively deplete regulatory T cells—the type of immune cells that suppress the immune response. Cambridge, MA-based Jounce has said that therapies targeting regulatory T cells may help address cancers that don’t respond to currently approved immunotherapies.
According to the deal terms announced Tuesday, Gilead (NASDAQ: GILD) will pay Jounce $85 million up front. The Foster City,... Read more »
Author: Frank Vinluan
Date : 2020-09-01T15:27:11.000Z